Robert W. Baird reissued their outperform rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note issued to investors on Tuesday. The firm currently has a $87.00 price target on the biopharmaceutical company’s stock.

GILD has been the topic of several other research reports. William Blair reiterated an outperform rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley reiterated an equal weight rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Credit Suisse Group reiterated an outperform rating and set a $79.00 price objective on shares of Gilead Sciences in a report on Friday, May 5th. Leerink Swann reiterated a hold rating and set a $74.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Zacks Investment Research upgraded Gilead Sciences from a hold rating to a buy rating and set a $84.00 price objective on the stock in a report on Friday, July 28th. Eleven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $82.09.

Shares of Gilead Sciences (NASDAQ GILD) traded down 1.56% during trading on Tuesday, hitting $82.40. The stock had a trading volume of 3,727,390 shares. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $84.13. The firm has a 50 day moving average of $74.02 and a 200 day moving average of $69.18. The company has a market capitalization of $107.61 billion, a price-to-earnings ratio of 8.95 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the business posted $3.08 EPS. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.73 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Earns “Outperform” Rating from Robert W. Baird” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-earns-outperform-rating-from-robert-w-baird/1536114.html.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is 22.58%.

In other news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Rockland Trust Co. increased its stake in Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. increased its stake in Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares during the last quarter. Berkshire Asset Management LLC PA bought a new stake in Gilead Sciences during the first quarter worth $270,000. Sigma Planning Corp increased its stake in Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares during the last quarter. Finally, Hollencrest Securities LLC increased its stake in Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares during the last quarter. Hedge funds and other institutional investors own 74.04% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.